Giulia Gregori1,2, Alessandra Celli1,2, Yoann Barnouin1,2, Arjun Paudyal1,2, Reina Armamento-Villareal1,2, Nicola Napoli3, Clifford Qualls4, Dennis T Villareal1,2. 1. Center for Translational Research on Inflammatory Diseases, Michael E DeBakey VA Medical Center, Houston, TX, USA. 2. Division of Endocrinology, Diabetes, and Metabolism, Baylor College of Medicine, Houston, TX, USA. 3. Division of Endocrinology and Metabolism, Washington University School of Medicine, St Louis, MO, USA. 4. Department of Mathematics and Statistics, University of New Mexico School of Medicine, Albuquerque, NM, USA.
Abstract
BACKGROUND: Both obesity and hypogonadism are common in older men which could additively exacerbate age-related declines in cognitive function. However, little is known about the effects of lifestyle intervention plus testosterone replacement therapy in this population. OBJECTIVES: In this secondary analysis of the LITROS (Lifestyle Intervention and Testosterone Replacement in Obese Seniors) trial, we examined whether testosterone replacement therapy would improve cognitive function when added to intensive lifestyle intervention in older men with obesity and hypogonadism. METHODS: Eighty-three older, obese hypogonadal men with frailty were randomly assigned to lifestyle therapy (weight management and exercise training) plus testosterone (LT + Test) or lifestyle therapy plus placebo (LT + Pbo) for 6 mo. For this report, the primary outcome was change in the global cognition composite z score. Secondary outcomes included changes in z score subcomponents: attention/information processing, memory, executive function, and language. Changes between groups were analyzed using mixed-model repeated-measures ANCOVAs following the intention-to-treat principle. RESULTS: Global cognition z score increased more in the LT + Test than in the LT + Pbo group (mean change: 0.49 compared with 0.21; between-group difference: -0.28; 95% CI: -0.45, -0.11; Cohen's d = 0.74). Moreover, attention/information z score and memory z score increased more in the LT + Test than in the LT + Pbo group (mean change: 0.55 compared with 0.23; between-group difference: -0.32; 95% CI: -0.55, -0.09; Cohen's d = 0.49 and mean change: 0.90 compared with 0.37; between-group difference: -0.53; 95% CI: -0.93, -0.13; Cohen's d = 1.43, respectively). Multiple regression analyses showed that changes in peak oxygen consumption, strength, total testosterone, and luteinizing hormone were independent predictors of the improvement in global cognition (R2 = 0.38; P < 0.001). CONCLUSIONS: These findings suggest that in the high-risk population of older men with obesity and hypogonadism, testosterone replacement may improve cognitive function with lifestyle behaviors controlled via lifestyle intervention therapy.This trial was registered at clinicaltrials.gov as NCT02367105. Published by Oxford University Press on behalf of the American Society for Nutrition 2021.
BACKGROUND: Both obesity and hypogonadism are common in older men which could additively exacerbate age-related declines in cognitive function. However, little is known about the effects of lifestyle intervention plus testosterone replacement therapy in this population. OBJECTIVES: In this secondary analysis of the LITROS (Lifestyle Intervention and Testosterone Replacement in Obese Seniors) trial, we examined whether testosterone replacement therapy would improve cognitive function when added to intensive lifestyle intervention in older men with obesity and hypogonadism. METHODS: Eighty-three older, obese hypogonadal men with frailty were randomly assigned to lifestyle therapy (weight management and exercise training) plus testosterone (LT + Test) or lifestyle therapy plus placebo (LT + Pbo) for 6 mo. For this report, the primary outcome was change in the global cognition composite z score. Secondary outcomes included changes in z score subcomponents: attention/information processing, memory, executive function, and language. Changes between groups were analyzed using mixed-model repeated-measures ANCOVAs following the intention-to-treat principle. RESULTS: Global cognition z score increased more in the LT + Test than in the LT + Pbo group (mean change: 0.49 compared with 0.21; between-group difference: -0.28; 95% CI: -0.45, -0.11; Cohen's d = 0.74). Moreover, attention/information z score and memory z score increased more in the LT + Test than in the LT + Pbo group (mean change: 0.55 compared with 0.23; between-group difference: -0.32; 95% CI: -0.55, -0.09; Cohen's d = 0.49 and mean change: 0.90 compared with 0.37; between-group difference: -0.53; 95% CI: -0.93, -0.13; Cohen's d = 1.43, respectively). Multiple regression analyses showed that changes in peak oxygen consumption, strength, total testosterone, and luteinizing hormone were independent predictors of the improvement in global cognition (R2 = 0.38; P < 0.001). CONCLUSIONS: These findings suggest that in the high-risk population of older men with obesity and hypogonadism, testosterone replacement may improve cognitive function with lifestyle behaviors controlled via lifestyle intervention therapy.This trial was registered at clinicaltrials.gov as NCT02367105. Published by Oxford University Press on behalf of the American Society for Nutrition 2021.
Authors: Dennis T Villareal; Suresh Chode; Nehu Parimi; David R Sinacore; Tiffany Hilton; Reina Armamento-Villareal; Nicola Napoli; Clifford Qualls; Krupa Shah Journal: N Engl J Med Date: 2011-03-31 Impact factor: 91.245
Authors: Cinta Valls-Pedret; Aleix Sala-Vila; Mercè Serra-Mir; Dolores Corella; Rafael de la Torre; Miguel Ángel Martínez-González; Elena H Martínez-Lapiscina; Montserrat Fitó; Ana Pérez-Heras; Jordi Salas-Salvadó; Ramon Estruch; Emilio Ros Journal: JAMA Intern Med Date: 2015-07 Impact factor: 21.873
Authors: Giuseppe Verdile; Prita R Asih; Anna M Barron; Eka J Wahjoepramono; Lars M Ittner; Ralph N Martins Journal: Horm Behav Date: 2015-06-27 Impact factor: 3.587
Authors: Mark A Espeland; José A Luchsinger; Laura D Baker; Rebecca Neiberg; Steven E Kahn; Steven E Arnold; Rena R Wing; George L Blackburn; George Bray; Mary Evans; Helen P Hazuda; Robert W Jeffery; Valerie M Wilson; Jeanne M Clark; Mace Coday; Kathryn Demos-McDermott; John P Foreyt; Frank Greenway; James O Hill; Edward S Horton; John M Jakicic; Karen C Johnson; William C Knowler; Cora E Lewis; David M Nathan; Anne Peters; Xavier Pi-Sunyer; Henry Pownall; Thomas A Wadden; Stephen R Rapp Journal: Neurology Date: 2017-04-26 Impact factor: 9.910
Authors: J Scott Andrews; Urvi Desai; Noam Y Kirson; Miriam L Zichlin; Daniel E Ball; Brandy R Matthews Journal: Alzheimers Dement (N Y) Date: 2019-08-02